Linezolid

• Type: Oxazolidinone antibiotic
• Dosage Forms: PO/IV
• Common Trade Names: Zyvox
• Bacteriostatic, so prefer another agent in bacteremia, such as ceftaroline in vancomycin resistant MRSA

• VRE infections:
  • 600 mg PO/IV Q12H x 14-28 days
• Pneumonia, community-acquired:
  • 600 mg PO/IV Q12H x 5 days
• Pneumonia, hospital-acquired or ventilator-associated:
  • 600 mg PO/IV Q12H x 5 days
• Uncomplicated skin infections:
  • 400 mg PO Q12H x 10-14 days
• Complicated skin infections:
  • 600 mg PO/IV Q12H x 10-14 days
• Endocarditis
  • 600 mg PO/IV Q12H x 6 weeks

• >12 years old: 600mg IV/PO q12h
• <12 years: 10mg/kg IV/PO q8-12h

• Pregnancy Rating: C
• Lactation: Infant risk cannot be ruled out
• Renal Dosing
  • Renal impairment: no adjustment
  • Hemodialysis: give dose after HD

Hepatic dosing: no adjustment for mild-moderate impairment (Child-Pugh Class A or B)

• Allergy to class/drug
• Use of MAOIs, concomitantly or within past 14 days

• Half-life: adults- 4.7-5.1h, pediatrics- 1.5-4.1
• Metabolism:
• Excretion:

• Antibiotics (Main)